Perrigo Q2 sales fall as it executes Three-S plan
Perrigo reported lower Q2 sales and margins but reaffirmed 2026 guidance, citing sequential improvement and portfolio streamlining via the sale of its Dermacosmetics business.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day